{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:12:29Z","timestamp":1793419949953,"version":"4.5.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T00:00:00Z","timestamp":1689984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T00:00:00Z","timestamp":1689984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Parkinson\u2019s disease (PD) is the second most frequent neurodegenerative disease associated with motor dysfunction secondary to the loss of dopaminergic neurons in the nigrostriatal axis. Actual therapy consists mainly of levodopa; however, its long-term use promotes secondary effects. Consequently, finding new therapeutic alternatives, such as neuroprotective molecules, is necessary. Among these alternatives is silybin (Sb), the major bioactive flavonolignan in silymarin. Both exert neuroprotective effects, preserving dopamine levels and dopaminergic neurons when administered in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse PD model, being probably Sb the potential therapeutic molecule behind this effect. To elucidate the role of Sb in the PD model, we determined the dose-dependent conservation of striatal dopamine content following Sb oral administration. Then, we evaluated motor deficit tests using the best dopamine conservative dose of Sb and determined a cytokine-dependent inflammatory profile status, malondialdehyde as an oxidative stress product, and neurotrophic factors content in the MPTP-induced mouse PD model. Our results show that oral Sb at 100 mg\/kg dose conserved about 60% dopamine levels. Also, Sb improved motor deficits, preserved neurotrophic factors content and mitochondrial function, reduced lipid peroxidation, diminished proinflammatory cytokines to basal levels, enhanced fractalkine production in the striatum and substantia nigra, and increased IL-10 and IL-4 levels in the substantia nigra in the MPTP mice. Thus, oral Sb may be a potential pharmacological PD treatment alternative.<\/jats:p>","DOI":"10.1007\/s12035-023-03485-7","type":"journal-article","created":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T02:01:32Z","timestamp":1689991292000},"page":"6774-6788","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Oral Administration of Silybin Protects Against MPTP-Induced Neurotoxicity by Reducing Pro-inflammatory Cytokines and Preserving BDNF Levels in Mice"],"prefix":"10.1007","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8032-806X","authenticated-orcid":false,"given":"Ricardo J.","family":"Ram\u00edrez-Carreto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor J.","family":"Zald\u00edvar-Machorro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6081-8539","authenticated-orcid":false,"given":"Dafne J.","family":"P\u00e9rez-Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5562-4644","authenticated-orcid":false,"given":"Blanca E.","family":"Rodr\u00edguez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Meza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperanza","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9874-7182","authenticated-orcid":false,"given":"Abel","family":"Santamar\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anah\u00ed","family":"Chavarr\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,22]]},"reference":[{"key":"3485_CR1","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.freeradbiomed.2013.01.018","volume":"62","author":"DT Dexter","year":"2013","unstructured":"Dexter DT, Jenner P (2013) Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med 62:132\u2013144","journal-title":"Free Radic Biol Med"},{"key":"3485_CR2","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","volume":"17","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Elbaz A, Nichols E, Abbasi N, Abd-Allah F, Abdelalim A et al (2018) Global, regional, and national burden of Parkinson\u2019s disease, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17:939\u2013953","journal-title":"Lancet Neurol"},{"issue":"5","key":"3485_CR3","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1212\/01.wnl.0000247740.47667.03","volume":"68","author":"ER Dorsey","year":"2007","unstructured":"Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K et al (2007) Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68(5):384\u2013386. https:\/\/doi.org\/10.1212\/01.wnl.0000247740.47667.03","journal-title":"Neurology"},{"key":"3485_CR4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3389\/fnagi.2017.00176\/full","volume":"9","author":"SR Subramaniam","year":"2017","unstructured":"Subramaniam SR, Federoff HJ (2017) Targeting microglial activation states as a therapeutic avenue in Parkinson\u2019s Disease. Front Aging Neurosci 9:176. https:\/\/doi.org\/10.3389\/fnagi.2017.00176\/full","journal-title":"Front Aging Neurosci"},{"key":"3485_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.lfs.2019.03.057","volume":"226","author":"C Raza","year":"2019","unstructured":"Raza C, Anjum R, N ulA S (2019) Parkinson\u2019s disease: mechanisms, translational models and management strategies. Life Sci 226:77\u201390","journal-title":"Life Sci"},{"issue":"9","key":"3485_CR6","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.nrl.2014.10.010","volume":"31","author":"K Berganzo","year":"2016","unstructured":"Berganzo K, Tijero B, Gonz\u00e1lez-Eizaguirre A, Somme J, Lezcano E, Gabilondo I et al (2016) Motor and non-motor symptoms of Parkinson\u2019s disease and their impact on quality of life and on different clinical subgroups. Neurolog\u00eda 31(9):585\u2013591","journal-title":"Neurolog\u00eda"},{"issue":"7","key":"3485_CR7","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrn.2017.62","volume":"18","author":"AHV Schapira","year":"2017","unstructured":"Schapira AHV, Chaudhuri KR, Jenner P (2017) Non-motor features of Parkinson disease. Nat Rev Neurosci 18(7):435\u2013450","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"3485_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/molecules23010040","volume":"23","author":"F Haddad","year":"2017","unstructured":"Haddad F, Sawalha M, Khawaja Y, Najjar A, Karaman R (2017) Dopamine and levodopa prodrugs for the treatment of Parkinson\u2019s Disease. Molecules 23(1):40","journal-title":"Molecules"},{"key":"3485_CR9","doi-asserted-by":"crossref","unstructured":"Francardo V, Cenci MA  Investigating the molecular mechanisms of L-DOPA-induced dyskinesia in the mouse. Parkinsonism Relat Disord 20:S20\u2013S22","DOI":"10.1016\/S1353-8020(13)70008-7"},{"issue":"11","key":"3485_CR10","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1002\/mds.26712","volume":"31","author":"J Nonnekes","year":"2016","unstructured":"Nonnekes J, Timmer MHM, de Vries NM, Rascol O, Helmich RC, Bloem BR (2016) Unmasking levodopa resistance in Parkinson\u2019s disease: Unmasking Levodopa Resistance IN PD. Mov Disord 31(11):1602\u20131609. https:\/\/doi.org\/10.1002\/mds.26712","journal-title":"Mov Disord"},{"issue":"3","key":"3485_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/9780470942390.mo140092","volume":"4","author":"W Bobela","year":"2014","unstructured":"Bobela W, Zheng L, Schneider BL (2014) Overview of mouse models of Parkinson\u2019s Disease: mouse models of Parkinson\u2019s Disease. Curr Protoc Mouse Biol 4(3):121\u2013139. https:\/\/doi.org\/10.1002\/9780470942390.mo140092","journal-title":"Curr Protoc Mouse Biol"},{"key":"3485_CR12","unstructured":"Casta\u00f1eda-Achutigu\u00ed F, Tejeda-Mart\u00ednez A, Escalante Casa\u00f1eda A, Sucres-Bernes HA, Monterrubio-Ledezma E, Garc\u00eda-Lemus R (2015) Modelos cl\u00e1sicos de inducci\u00f3n de Parkinson. Neurobiolog\u00eda 6(13)"},{"key":"3485_CR13","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.foodres.2017.07.017","volume":"100","author":"CS Chambers","year":"2017","unstructured":"Chambers CS, Hole\u010dkov\u00e1 V, Petr\u00e1skov\u00e1 L, Biedermann D, Valentov\u00e1 K, Buchta M et al (2017) The silymarin composition\u2026 and why does it matter??? Food Res Int 100:339\u2013353","journal-title":"Food Res Int"},{"issue":"13","key":"3485_CR14","doi-asserted-by":"publisher","first-page":"5995","DOI":"10.1073\/pnas.0914009107","volume":"107","author":"SJ Polyak","year":"2010","unstructured":"Polyak SJ, Morishima C, Lohmann V, Pal S, Lee DYW, Liu Y et al (2010) Identification of hepatoprotective flavonolignans from silymarin. Proc Natl Acad Sci 107(13):5995\u20135999. https:\/\/doi.org\/10.1073\/pnas.0914009107","journal-title":"Proc Natl Acad Sci"},{"key":"3485_CR15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.tox.2014.02.009","volume":"319","author":"J P\u00e9rez-H","year":"2014","unstructured":"P\u00e9rez-H J, Carrillo-S C, Garc\u00eda E, Ruiz-Mar G, P\u00e9rez-Tamayo R, Chavarr\u00eda A (2014) Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson\u2019s disease. Toxicology 319:38\u201343","journal-title":"Toxicology"},{"issue":"1","key":"3485_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0944-7113(00)80017-3","volume":"7","author":"OP Gupta","year":"2000","unstructured":"Gupta OP, Sing S, Bani S, Sharma N, Malhotra S, Gupta BD et al (2000) Anti-inflammatory and anti-arthritic activities of silymarin acting through inhibition of 5-lipoxygenase. Phytomedicine 7(1):21\u201324","journal-title":"Phytomedicine"},{"issue":"12","key":"3485_CR17","doi-asserted-by":"publisher","first-page":"6800","DOI":"10.4049\/jimmunol.163.12.6800","volume":"163","author":"SK Manna","year":"1999","unstructured":"Manna SK, Mukhopadhyay A, Van NT, Aggarwal BB (1999) Silymarin Suppresses TNF-Induced Activation of NF-\u03baB, c-Jun N-Terminal Kinase, and Apoptosis. J Immunol 163(12):6800\u20136809","journal-title":"J Immunol"},{"key":"3485_CR18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.indcrop.2015.03.060","volume":"70","author":"DR de Oliveira","year":"2015","unstructured":"de Oliveira DR, Schaffer LF, Busanello A, Barbosa CP, Peroza LR, de Freitas CM et al (2015) Silymarin has antioxidant potential and changes the activity of Na+\/K+-ATPase and monoamine oxidase in vitro. Ind Crops Prod 70:347\u2013355","journal-title":"Ind Crops Prod"},{"issue":"3","key":"3485_CR19","first-page":"297","volume":"27","author":"P Hern\u00e1ndez-Ram\u00edrez","year":"2011","unstructured":"Hern\u00e1ndez-Ram\u00edrez P (2011) La mucosa nasal como v\u00eda y fuente para la medicina regenerativa. Revista Cubana de Hematolog\u00eda, Inmunolog\u00eda y Hemoterapia 27(3):297\u2013308","journal-title":"Revista Cubana de Hematolog\u00eda, Inmunolog\u00eda y Hemoterapia"},{"issue":"5","key":"3485_CR20","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/jnr.23544","volume":"93","author":"Y Lee","year":"2015","unstructured":"Lee Y, Park HR, Chun HJ, Lee J (2015) Silibinin prevents dopaminergic neuronal loss in a mouse model of Parkinson\u2019s disease via mitochondrial stabilization: Neuroprotective Effects of Silibinin in a PD Model. J Neurosci Res 93(5):755\u2013765. https:\/\/doi.org\/10.1002\/jnr.23544","journal-title":"J Neurosci Res"},{"key":"3485_CR21","doi-asserted-by":"publisher","first-page":"113510","DOI":"10.1016\/j.physbeh.2021.113510","volume":"239","author":"X Liu","year":"2021","unstructured":"Liu X, Liu W, Wang C, Chen Y, Liu P, Hayashi T et al (2021) Silibinin attenuates motor dysfunction in a mouse model of Parkinson\u2019s disease by suppression of oxidative stress and neuroinflammation along with promotion of mitophagy. Physiol Behav 239:113510","journal-title":"Physiol Behav"},{"key":"3485_CR22","volume-title":"AVMA Guidelines for the Euthanasia of Animals","author":"S Leary","year":"2020","unstructured":"Leary S, Pharmaceuticals F, Underwood W, Anthony R, Cartner S, Johnson CL, et al. AVMA Guidelines for the Euthanasia of Animals: 2020 Edition. 2020;121.","edition":"2020"},{"key":"3485_CR23","unstructured":"Mu\u00f1oz LIO. NORMA OFICIAL MEXICANA NOM-062-ZOO-1999, ESPECIFICACIONES TECNICAS PARA LA PRODUCCION, CUIDADO Y USO DE LOS ANIMALES DE LABORATORIO. [Internet]. Diario Oficial de la Federaci\u00f3n, NOM-062-ZOO-1999 2001 p. 59"},{"key":"3485_CR24","volume-title":"Guidelines for the Care and Use of Mammals in Neuroscience and Behavioral Research [Internet]. 1\u00b0. Vol. 1","author":"National Research Council of the NA","year":"2003","unstructured":"National Research Council of the NA (2003) Guidelines for the Care and Use of Mammals in Neuroscience and Behavioral Research [Internet]. 1\u00b0. Vol. 1. National Academies Press, Washington, D.C"},{"issue":"10","key":"3485_CR25","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1080\/10715760802506356","volume":"42","author":"E Garcia","year":"2008","unstructured":"Garcia E, Limon D, Perez-De La Cruz V, Giordano M, Diaz-Mu\u00f1oz M, Maldonado PD et al (2008) Lipid peroxidation, mitochondrial dysfunction and neurochemical and behavioural deficits in different neurotoxic models: Protective role of S-allylcysteine. Free Radic Res 42(10):892\u2013902. https:\/\/doi.org\/10.1080\/10715760802506356","journal-title":"Free Radic Res"},{"issue":"4","key":"3485_CR26","first-page":"700","volume":"10","author":"S Rezaee","year":"2018","unstructured":"Rezaee S, Jahromy MH (2018) Potential Effects of Pomegranate Juice in Attenuating LID in Mice Model of Parkinson Disease. Pharma J 10(4):700\u2013704","journal-title":"Pharma J"},{"issue":"4","key":"3485_CR27","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/S0306-4522(96)00545-3","volume":"77","author":"NA Tatton","year":"1997","unstructured":"Tatton NA, Kish SJ (1997) In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 77(4):1037\u20131048","journal-title":"Neuroscience"},{"key":"3485_CR28","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2147\/DDDT.S156920","volume":"12","author":"M Hu","year":"2018","unstructured":"Hu M, Li F, Wang W (2018) Vitexin protects dopaminergic neurons in MPTP-induced Parkinson&rsquo;s disease through PI3K\/Akt signaling pathway. DDDT 12:565\u2013573","journal-title":"DDDT"},{"issue":"8\u20139","key":"3485_CR29","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/j.fct.2010.05.002","volume":"48","author":"MS Ju","year":"2010","unstructured":"Ju MS, Kim HG, Choi JG, Ryu JH, Hur J, Kim YJ et al (2010) Cassiae semen, a seed of Cassia obtusifolia, has neuroprotective effects in Parkinson\u2019s disease models. Food Chem Toxicol 48(8\u20139):2037\u20132044","journal-title":"Food Chem Toxicol"},{"issue":"42","key":"3485_CR30","doi-asserted-by":"publisher","first-page":"9434","DOI":"10.1523\/JNEUROSCI.3080-04.2004","volume":"24","author":"SM Fleming","year":"2004","unstructured":"Fleming SM (2004) Early and Progressive Sensorimotor Anomalies in Mice Overexpressing Wild-Type Human -Synuclein. J Neurosci 24(42):9434\u20139440. https:\/\/doi.org\/10.1523\/JNEUROSCI.3080-04.2004","journal-title":"J Neurosci"},{"issue":"3","key":"3485_CR31","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1023\/A:1001958023096","volume":"30","author":"M Sedelis","year":"2000","unstructured":"Sedelis M, Hofele K, Auburger GW, Morgan S, Huston JP, Schwarting RKW (2000) MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav Genet 30(3):171\u2013182. https:\/\/doi.org\/10.1023\/A:1001958023096","journal-title":"Behav Genet"},{"issue":"3","key":"3485_CR32","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s13311-019-00719-2","volume":"16","author":"ZL Zhou","year":"2019","unstructured":"Zhou ZL, Jia XB, Sun MF, Zhu YL, Qiao CM, Zhang BP et al (2019) Neuroprotection of fasting mimicking diet on MPTP-induced Parkinson\u2019s disease mice via gut microbiota and metabolites. Neurotherapeutics 16(3):741\u2013760. https:\/\/doi.org\/10.1007\/s13311-019-00719-2","journal-title":"Neurotherapeutics"},{"issue":"4","key":"3485_CR33","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s13311-017-0544-9","volume":"14","author":"F Richter","year":"2017","unstructured":"Richter F, Subramaniam SR, Magen I, Lee P, Hayes J, Attar A et al (2017) A molecular tweezer ameliorates motor deficits in mice overexpressing \u03b1-Synuclein. Neurotherapeutics 14(4):1107\u20131119. https:\/\/doi.org\/10.1007\/s13311-017-0544-9","journal-title":"Neurotherapeutics"},{"key":"3485_CR34","unstructured":"RMJ D (2013) Measuring the Strength of Mice. JoVE (76):2610"},{"key":"3485_CR35","unstructured":"RMJ D (2013) Measuring Motor Coordination in Mice. JoVE (75):2609"},{"issue":"2","key":"3485_CR36","first-page":"189","volume":"15","author":"LB Lezcano","year":"2010","unstructured":"Lezcano LB, Pedre LDCL, Verdecia CIF, S\u00e1nchez TS, Fuentes NP, Turner LF (2010) Aplicaci\u00f3n Del Test De La Barra Transversal Modificado Para Evaluar Ratas Hemiparkinsonizadas. Acta Biol Colomb 15(2):189\u2013201","journal-title":"Acta Biol Colomb"},{"key":"3485_CR37","doi-asserted-by":"crossref","unstructured":"Fleming SM, Ekhator OR, Ghisays V (2013) Assessment of sensorimotor function in mouse models of Parkinson\u2019s Disease. JoVE (76):50303","DOI":"10.3791\/50303"},{"key":"3485_CR38","doi-asserted-by":"crossref","unstructured":"Luong TN, Carlisle HJ, Southwell A, Patterson PH (2011) Assessment of motor balance and coordination in mice using the balance beam. JoVE (49):2376","DOI":"10.3791\/2376"},{"issue":"2","key":"3485_CR39","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jneumeth.2006.07.006","volume":"159","author":"HN Allbutt","year":"2007","unstructured":"Allbutt HN, Henderson JM (2007) Use of the narrow beam test in the rat, 6-hydroxydopamine model of Parkinson\u2019s disease. J Neurosci Methods 159(2):195\u2013202","journal-title":"J Neurosci Methods"},{"issue":"5","key":"3485_CR40","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.brainresbull.2005.09.013","volume":"68","author":"VPD La Cruz","year":"2006","unstructured":"La Cruz VPD, Gonz\u00e1lez-Cort\u00e9s C, Pedraza-Chaverr\u00ed J, Maldonado PD, Andr\u00e9s-Mart\u00ednez L, Santamar\u00eda A (2006) Protective effect of S-allylcysteine on 3-nitropropionic acid-induced lipid peroxidation and mitochondrial dysfunction in rat brain synaptosomes. Brain Res Bull 68(5):379\u2013383","journal-title":"Brain Res Bull"},{"key":"3485_CR41","doi-asserted-by":"publisher","unstructured":"Sornsuvit C, Hongwiset D, Yotsawimonwat S, Toonkum M, Thongsawat S, Taesotikul W (2018, 2018) The bioavailability and pharmacokinetics of silymarin SMEDDS formulation study in healthy Thai volunteers. Evid Based Complement Alternat Med:1507834. https:\/\/doi.org\/10.1155\/2018\/1507834","DOI":"10.1155\/2018\/1507834"},{"issue":"11","key":"3485_CR42","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.3390\/molecules24112155","volume":"24","author":"A Di Costanzo","year":"2019","unstructured":"Di Costanzo A, Angelico R (2019) Formulation strategies for enhancing the bioavailability of silymarin: the state of the art. Molecules 24(11):2155. https:\/\/doi.org\/10.3390\/molecules24112155","journal-title":"Molecules"},{"key":"3485_CR43","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3389\/fnins.2018.00342","volume":"12","author":"S Franco-Iborra","year":"2018","unstructured":"Franco-Iborra S, Vila M, Perier C (2018) Mitochondrial Quality Control in Neurodegenerative Diseases: Focus on Parkinson\u2019s Disease and Huntington\u2019s Disease. Front Neurosci 12:342. https:\/\/doi.org\/10.3389\/fnins.2018.00342","journal-title":"Front Neurosci"},{"key":"3485_CR44","doi-asserted-by":"publisher","first-page":"894","DOI":"10.3389\/fnins.2019.00894\/full","volume":"13","author":"I Gonz\u00e1lez-Casacuberta","year":"2019","unstructured":"Gonz\u00e1lez-Casacuberta I, Ju\u00e1rez-Flores DL, Mor\u00e9n C, Garrabou G (2019) Bioenergetics and autophagic imbalance in patients-derived cell models of Parkinson Disease supports systemic dysfunction in neurodegeneration. Front Neurosci 13:894. https:\/\/doi.org\/10.3389\/fnins.2019.00894\/full","journal-title":"Front Neurosci"},{"issue":"5","key":"3485_CR45","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11910-018-0829-3","volume":"18","author":"JS Park","year":"2018","unstructured":"Park JS, Davis RL, Sue CM (2018) Mitochondrial dysfunction in Parkinson\u2019s Disease: new mechanistic insights and therapeutic perspectives. Curr Neurol Neurosci Rep 18(5):21","journal-title":"Curr Neurol Neurosci Rep"},{"key":"3485_CR46","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.freeradbiomed.2016.04.012","volume":"100","author":"R Requejo-Aguilar","year":"2016","unstructured":"Requejo-Aguilar R, Bola\u00f1os JP (2016) Mitochondrial control of cell bioenergetics in Parkinson\u2019s disease. Free Radic Biol Med 100:123\u2013137","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"3485_CR47","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41531-018-0044-6","volume":"4","author":"AK Reeve","year":"2018","unstructured":"Reeve AK, Grady JP, Cosgrave EM, Bennison E, Chen C, Hepplewhite PD et al (2018) Mitochondrial dysfunction within the synapses of substantia nigra neurons in Parkinson\u2019s disease. NPJ Parkinson\u2019s Dis 4(1):9","journal-title":"NPJ Parkinson\u2019s Dis"},{"issue":"1","key":"3485_CR48","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.molbrainres.2004.09.017","volume":"134","author":"RJ Smeyne","year":"2005","unstructured":"Smeyne RJ, Jackson-Lewis V (2005) The MPTP model of Parkinson\u2019s disease. Mol Brain Res 134(1):57\u201366","journal-title":"Mol Brain Res"},{"key":"3485_CR49","doi-asserted-by":"publisher","unstructured":"Bondarenko O, Saarma M (2021) Neurotrophic factors in Parkinson\u2019s Disease: clinical trials, open challenges and nanoparticle-mediated delivery to the brain. Front Cell Neurosci 15. https:\/\/doi.org\/10.3389\/fncel.2021.682597","DOI":"10.3389\/fncel.2021.682597"},{"issue":"1","key":"3485_CR50","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jneumeth.2005.04.005","volume":"148","author":"MM Ferro","year":"2005","unstructured":"Ferro MM, Bellissimo MI, Anselmo-Franci JA, Angellucci MEM, Canteras NS, Da Cunha C (2005) Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson\u2019s disease: histological, neurochemical, motor and memory alterations. J Neurosci Met 148(1):78\u201387","journal-title":"J Neurosci Met"},{"issue":"31","key":"3485_CR51","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.2174\/0929867325666180313101536","volume":"25","author":"RN Ferreira","year":"2023","unstructured":"Ferreira RN, AS de M, Rocha NP, Silva ACS, e, Teixeira AL, Camargos ER da S. (2023) Neurotrophic factors in Parkinson\u2019s Disease: what have we learned from pre-clinical and clinical studies? Curr Med Chem 25(31):3682\u20133702","journal-title":"Curr Med Chem"},{"key":"3485_CR52","doi-asserted-by":"publisher","first-page":"860","DOI":"10.3389\/fneur.2018.00860","volume":"9","author":"P Troncoso-Escudero","year":"2018","unstructured":"Troncoso-Escudero P, Parra A, Nassif M, Vidal RL (2018) Outside in: unraveling the role of neuroinflammation in the progression of Parkinson\u2019s Disease. Front Neurol 9:860","journal-title":"Front Neurol"},{"issue":"5","key":"3485_CR53","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1007\/s12035-018-1283-6","volume":"56","author":"B Lima Giacobbo","year":"2019","unstructured":"Lima Giacobbo B, Doorduin J, Klein HC, Dierckx RAJO, Bromberg E, EFJ d V (2019) Brain-derived neurotrophic factor in brain disorders: focus on neuroinflammation. Mol Neurobiol 56(5):3295\u20133312","journal-title":"Mol Neurobiol"},{"issue":"1","key":"3485_CR54","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40035-015-0042-0","volume":"4","author":"Q Wang","year":"2015","unstructured":"Wang Q, Liu Y, Zhou J (2015) Neuroinflammation in Parkinson\u2019s disease and its potential as therapeutic target. Transl Neurodegener 4(1):19","journal-title":"Transl Neurodegener"},{"issue":"3","key":"3485_CR55","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.3390\/ijms21031170","volume":"21","author":"E Palasz","year":"2020","unstructured":"Palasz E, Wysocka A, Gasiorowska A, Chalimoniuk M, Niewiadomski W, Niewiadomska G (2020) BDNF as a promising therapeutic agent in Parkinson\u2019s Disease. IJMS 21(3):1170","journal-title":"IJMS"},{"key":"3485_CR56","doi-asserted-by":"publisher","first-page":"112365","DOI":"10.1016\/j.msec.2021.112365","volume":"129","author":"Q Huo","year":"2021","unstructured":"Huo Q, Shi Y, Qi Y, Huang L, Sui H, Zhao L (2021) Biomimetic silibinin-loaded macrophage-derived exosomes induce dual inhibition of A\u03b2 aggregation and astrocyte activation to alleviate cognitive impairment in a model of Alzheimer\u2019s disease. Mater Sci Eng C 129:112365","journal-title":"Mater Sci Eng C"},{"issue":"2","key":"3485_CR57","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1007\/s12035-014-9062-5","volume":"53","author":"M Wang","year":"2016","unstructured":"Wang M, Li YJ, Ding Y, Zhang HN, Sun T, Zhang K et al (2016) Silibinin prevents autophagic cell death upon oxidative stress in cortical neurons and cerebral ischemia-reperfusion injury. Mol Neurobiol 53(2):932\u2013943","journal-title":"Mol Neurobiol"},{"key":"3485_CR58","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1600-079X.2010.00819.x","volume":"2","author":"NK Singhal","year":"2010","unstructured":"Singhal NK, Srivastava G, Patel DK, Jain SK, Singh MP (2010) Melatonin or silymarin reduces maneb- and paraquat-induced Parkinson\u2019s disease phenotype in the mouse: Silymarin, melatonin and Parkinson\u2019s disease. J Pineal Res 2:97\u2013109. https:\/\/doi.org\/10.1111\/j.1600-079X.2010.00819.x","journal-title":"J Pineal Res"},{"issue":"3","key":"3485_CR59","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5688\/aj700371","volume":"70","author":"LC Fuhrman","year":"2006","unstructured":"Fuhrman LC (2006) Ansel\u2019s pharmaceutical dosage forms and drug delivery systems, 8th Edition. Am J Pharm Educ 70(3):71","journal-title":"Am J Pharm Educ"},{"key":"3485_CR60","volume-title":"Manual de Tecnolog\u00eda farmac\u00e9utica","author":"L Madel C","year":"2022","unstructured":"Lozano Madel C, C\u00f3rdoba D, C\u00f3rdoba M. Manual de Tecnolog\u00eda farmac\u00e9utica 2022"},{"issue":"1","key":"3485_CR61","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.taap.2007.02.015","volume":"222","author":"EJ Calabrese","year":"2007","unstructured":"Calabrese EJ, Bachmann KA, Bailer AJ, Bolger PM, Borak J, Cai L et al (2007) Biological stress response terminology: integrating the concepts of adaptive response and preconditioning stress within a hormetic dose\u2013response framework. Toxicol Appl Pharmacol 222(1):122\u2013128","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"3485_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.arr.2007.08.007","volume":"7","author":"MP Mattson","year":"2008","unstructured":"Mattson MP (2008) Hormesis defined. Ageing Res Rev 7(1):1\u20137","journal-title":"Ageing Res Rev"},{"key":"3485_CR63","doi-asserted-by":"publisher","unstructured":"Ricci PF, Straja SR, Cox AL  Changing the risk paradigms can be good for our health: J-shaped, linear and threshold dose-response models. Dose-Resp 10(2). https:\/\/doi.org\/10.2203\/dose-response.11-020.Ricci","DOI":"10.2203\/dose-response.11-020.Ricci"},{"issue":"1","key":"3485_CR64","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12967-020-02223-0","volume":"18","author":"I Castilla-Cort\u00e1zar","year":"2020","unstructured":"Castilla-Cort\u00e1zar I, Aguirre GA, Femat-Rold\u00e1n G, Mart\u00edn-Estal I, Espinosa L (2020) Is insulin-like growth factor-1 involved in Parkinson\u2019s disease development? J Transl Med 18(1):70. https:\/\/doi.org\/10.1186\/s12967-020-02223-0","journal-title":"J Transl Med"},{"issue":"1","key":"3485_CR65","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.brainres.2005.01.052","volume":"1039","author":"SA Baker","year":"2005","unstructured":"Baker SA, Stanford LE, Brown RE, Hagg T (2005) Maturation but not survival of dopaminergic nigrostriatal neurons is affected in developing and aging BDNF-deficient mice. Brain Res 1039(1):177\u2013188","journal-title":"Brain Res"},{"issue":"5","key":"3485_CR66","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s43440-020-00120-3","volume":"72","author":"P Chmielarz","year":"2020","unstructured":"Chmielarz P, Saarma M (2020) Neurotrophic factors for disease-modifying treatments of Parkinson\u2019s disease: gaps between basic science and clinical studies. Pharmacol Rep 72(5):1195\u20131217. https:\/\/doi.org\/10.1007\/s43440-020-00120-3","journal-title":"Pharmacol Rep"},{"issue":"6315","key":"3485_CR67","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/350230a0","volume":"350","author":"C Hyman","year":"1991","unstructured":"Hyman C, Hofer M, Barde YA, Juhasz M, Yancopoulos GD, Squinto SP et al (1991) BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350(6315):230\u2013232","journal-title":"Nature"},{"issue":"12","key":"3485_CR68","doi-asserted-by":"publisher","first-page":"e0144755","DOI":"10.1371\/journal.pone.0144755","volume":"10","author":"DH Li","year":"2015","unstructured":"Li DH, He YC, Quinn TJ, Liu J (2015) Serum insulin-like growth factor-1 in patients with de novo, drug na\u00efve Parkinson\u2019s Disease: a meta-analysis. PLOS ONE 10(12):e0144755. https:\/\/doi.org\/10.1371\/journal.pone.0144755","journal-title":"PLOS ONE"},{"issue":"4","key":"3485_CR69","doi-asserted-by":"publisher","first-page":"E734","DOI":"10.1152\/ajpendo.00071.2020","volume":"319","author":"XW Wang","year":"2020","unstructured":"Wang XW, Yuan LJ, Yang Y, Zhang M, Chen WF (2020) IGF-1 inhibits MPTP\/MPP+-induced autophagy on dopaminergic neurons through the IGF-1R\/PI3K-Akt-mTOR pathway and GPER. Am J Physiol - Endocrinol Metab 319(4):E734\u2013E743. https:\/\/doi.org\/10.1152\/ajpendo.00071.2020","journal-title":"Am J Physiol - Endocrinol Metab"},{"issue":"4","key":"3485_CR70","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.numecd.2005.05.003","volume":"15","author":"D Del Rio","year":"2005","unstructured":"Del Rio D, Stewart AJ, Pellegrini N (2005) A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis 15(4):316\u2013328","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"5","key":"3485_CR71","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1089\/jmf.2013.2926","volume":"17","author":"UJ Jung","year":"2014","unstructured":"Jung UJ, Jeon MT, Choi MS, Kim SR (2014) Silibinin Attenuates MPP + -induced neurotoxicity in the substantia nigra in vivo. J Med Food 17(5):599\u2013605. https:\/\/doi.org\/10.1089\/jmf.2013.2926","journal-title":"J Med Food"},{"issue":"1","key":"3485_CR72","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1124\/jpet.109.155069","volume":"331","author":"P Lu","year":"2009","unstructured":"Lu P, Mamiya T, Lu LL, Mouri A, Niwa M, Hiramatsu M et al (2009) Silibinin Attenuates Amyloid \u03b2 25\u201335 Peptide-Induced Memory Impairments: Implication of Inducible Nitric-Oxide Synthase and Tumor Necrosis Factor-\u03b1 in Mice. J Pharmacol Exp Ther 331(1):319\u2013326. https:\/\/doi.org\/10.1124\/jpet.109.155069","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"3485_CR73","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s11064-016-2141-4","volume":"42","author":"X Song","year":"2017","unstructured":"Song X, Zhou B, Cui L, Lei D, Zhang P, Yao G et al (2017) Silibinin ameliorates A\u03b225-35-induced memory deficits in rats by modulating autophagy and attenuating neuroinflammation as well as oxidative stress. Neurochem Res 42(4):1073\u20131083. https:\/\/doi.org\/10.1007\/s11064-016-2141-4","journal-title":"Neurochem Res"},{"key":"3485_CR74","doi-asserted-by":"publisher","unstructured":"Linnerbauer M, Rothhammer V (2020) Protective functions of reactive astrocytes following central nervous system insult. Front Immunol 11. https:\/\/doi.org\/10.3389\/fimmu.2020.573256\/full","DOI":"10.3389\/fimmu.2020.573256\/full"},{"issue":"5","key":"3485_CR75","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1021\/jp075814h","volume":"112","author":"P Trouillas","year":"2008","unstructured":"Trouillas P, Marsal P, Svobodov\u00e1 A, Vost\u00e1lov\u00e1 J, Gaz\u00e1k R, Hrb\u00e1c J, Sedmera P, Kren V, Lazzaroni R, Duroux JL, Walterov\u00e1 D (2008) Mechanism of the antioxidant action of silybin and 2,3-dehydrosilybin flavonolignans: a joint experimental and theoretical study. J Phys Chem A 112(5):1054\u20131063. https:\/\/doi.org\/10.1021\/jp075814h","journal-title":"J Phys Chem A"},{"key":"3485_CR76","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.3389\/fimmu.2018.01903\/full","volume":"9","author":"ML Dupuis","year":"2018","unstructured":"Dupuis ML, Conti F, Maselli A, Pagano MT, Ruggieri A, Anticoli S, Fragale A, Gabriele L, Gagliardi MC, Sanchez M, Ceccarelli F, Alessandri C, Valesini G, Ortona E, Pierdominici M (2018) The natural agonist of estrogen receptor \u03b2 silibinin plays an immunosuppressive role representing a potential therapeutic tool in rheumatoid arthritis. Front Immunol 9:1903. https:\/\/doi.org\/10.3389\/fimmu.2018.01903\/full","journal-title":"Front Immunol"},{"key":"3485_CR77","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.biopha.2018.01.128","volume":"102","author":"J Yang","year":"2018","unstructured":"Yang J, Sun Y, Xu F, Liu W, Hayashi T, Onodera S, Tashiro SI, Ikejima T (2018) Involvement of estrogen receptors in silibinin protection of pancreatic \u03b2-cells from TNF\u03b1- or IL-1\u03b2-induced cytotoxicity. Biomed Pharmacother 102:344\u2013353. https:\/\/doi.org\/10.1016\/j.biopha.2018.01.128","journal-title":"Biomed Pharmacother"},{"issue":"Pt B","key":"3485_CR78","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.fct.2018.04.028","volume":"116","author":"S Verdura","year":"2018","unstructured":"Verdura S, Cuy\u00e0s E, Llorach-Par\u00e9s L, P\u00e9rez-S\u00e1nchez A, Micol V, Nonell-Canals A, Joven J, Valiente M, S\u00e1nchez-Mart\u00ednez M, Bosch-Barrera J, Menendez JA (2018) Silibinin is a direct inhibitor of STAT3. Food Chem Toxicol 116(Pt B):161\u2013172. https:\/\/doi.org\/10.1016\/j.fct.2018.04.028","journal-title":"Food Chem Toxicol"},{"issue":"16","key":"3485_CR79","doi-asserted-by":"publisher","first-page":"5327","DOI":"10.3390\/molecules27165327","volume":"27","author":"K Wadhwa","year":"2022","unstructured":"Wadhwa K, Pahwa R, Kumar M, Kumar S, Sharma PC, Singh G, Verma R, Mittal V, Singh I, Kaushik D, Jeandet P (2022) Mechanistic insights into the pharmacological significance of silymarin. Molecules 27(16):5327","journal-title":"Molecules"},{"key":"3485_CR80","doi-asserted-by":"publisher","first-page":"113718","DOI":"10.1016\/j.biopha.2022.113718","volume":"155","author":"M Pang","year":"2022","unstructured":"Pang M, Peng R, Wang Y, Zhu Y, Wang P, Moussian B, Su Y, Liu X, Ming D (2022) Molecular understanding of the translational models and the therapeutic potential natural products of Parkinson's disease. Biomed Pharmacother 155:113718. https:\/\/doi.org\/10.1016\/j.biopha.2022.113718","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"3485_CR81","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s11011-022-00931-8","volume":"37","author":"A Mohammadipour","year":"2022","unstructured":"Mohammadipour A (2022) A focus on natural products for preventing and cure of mitochondrial dysfunction in Parkinson's disease. Metab Brain Dis 37(4):889\u2013900. https:\/\/doi.org\/10.1007\/s11011-022-00931-8","journal-title":"Metab Brain Dis"},{"issue":"1","key":"3485_CR82","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2174\/1389200217666160709204826","volume":"18","author":"M Solayman","year":"2023","unstructured":"Solayman M, Islam MA, Alam F, Khalil MI, Kamal MA, Gan SH (2023) Natural products combating neurodegeneration: Parkinson's Disease. Curr Drug Metab 18(1):50\u201361. https:\/\/doi.org\/10.2174\/1389200217666160709204826","journal-title":"Curr Drug Metab"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-023-03485-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-023-03485-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-023-03485-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T10:29:21Z","timestamp":1700476161000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-023-03485-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,22]]},"references-count":82,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["3485"],"URL":"https:\/\/doi.org\/10.1007\/s12035-023-03485-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2561579\/v1","asserted-by":"object"}]},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,22]]},"assertion":[{"value":"7 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental procedures were performed following the Mexican Official Law of Animal Protection NOM-062-ZOO-1999 [\n                      \n                      ] and the Guidelines for the Use of Animals in Neuroscience Research of the Society of Neuroscience [\n                      \n                      ]. Ethics, Research, and the Internal Committee for the Care and Use of Laboratory Animals (CICUAL) committees of Facultad de Medicina, UNAM, approved all experimental procedures (FM\/DI\/127\/2018, and CICUAL 001-CIC-2019). We reduced the number of mice used and their suffering or pain as much as possible.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}